Open an account

Tema Oncology ETF

CANC · ETF

$41.29−$0.2081 (−0.50%)TodayMarket closed ·
Prev close $41.50

About CANC

CANC was created on 2023-08-15 by Tema. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 203.44m in AUM and 59 holdings. CANC is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations.

Issuer
Tema
Expense ratio
0.75%
Assets under management
$211.78M
Inception
Aug 15, 2023
Asset class
Equity
Website
temaetfs.com

CANC key statistics

Price-earnings ratio
0.00
Average volume
26.92K
Volume
12.56K
Open price
$41.05
High today
$41.41
Low today
$40.61
52 Week high
$47.00
52 Week low
$29.65

Tema Oncology ETF (CANC) at a glance

Tema Oncology ETF (CANC) last traded at $41.29, with a price-to-earnings ratio of 0.00.

Today the fund has traded between $40.61 and $41.41. The current price is 1.7% above the day's low and 0.3% below its high.

Volume so far is 12.56K shares, below the average of 26.92K shares a day.

Over the past year Tema Oncology ETF has ranged from $29.65 to $47.00, and now sits 67% of the way up that range.

CANC news

  • Chandrima Sanyal

    EXCLUSIVE: AI, Genomics Could Fuel Biotech ETF Re-Rating as Health Care Trades at Discount, Says Expert

  • Vandana Singh

    Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application

  • Press releaseBusiness Wire

    Tema's Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.